Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065179 · ClinicalTrials.gov registry record · Phase 2
SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
A Phase 2 study of Kidney Cancer and Kidney Cancer Metastatic, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT03065179 is a Phase 2 study of Kidney Cancer and Kidney Cancer Metastatic that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 29 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03065179, a Phase 2 study of Kidney Cancer and Kidney Cancer Metastatic, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-institution, single-arm phase II study to determine the safety and efficacy of SBRT (up to 2 metastatic sites preferentially lung, mediastinum or bone in combination of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma(with a clear-cell component and at least 1 measurable metastatic lesion that is not being irradiated).
Conditions Studied
Interventions
- RADIATION SBRT
- DRUG Nivolumab/Ipilimumab
Study Locations (2)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Texas
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2020-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03065179
The ClinicalTrials.gov registry entry for NCT03065179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which SBRT is the first listed.
NCT03065179 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT03065179 about?
NCT03065179 is a clinical study titled "SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients". This is a multi-institution, single-arm phase II study to determine the safety and efficacy of SBRT (up to 2 metastatic sites preferentially lung, mediastinum or bone in combination of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma(with a clear-cell component and at least ...
What is the current status of trial NCT03065179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2017-03-01. Estimated completion is 2020-11-17.
What conditions does trial NCT03065179 study?
This clinical trial studies the following conditions: Kidney Cancer, Kidney Cancer Metastatic, Kidney Cancer, Stage IV.
What interventions are being tested in trial NCT03065179?
The interventions under investigation include: SBRT (RADIATION), Nivolumab/Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03065179?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03065179 being conducted?
This trial has 2 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.